About Us
Management | Fact Sheet (PDF) | Careers
Corporate Officers
Frederick L. Hall, Ph.D.
Founder, President and CEO, CSO
Prior to founding the Company, Dr. Hall served for 12 years at the University of Southern California School of Medicine: as Director of Research in the Departments of Orthopaedic Surgery, Cardiothoracic Surgery, and Colorectal Surgery, and as Associate Professor of Molecular Pharmacology and Toxicology at the USC School of Pharmacy. Epeius Biotechnologies was incubated at the University of Southern California School of Medicine, under the steadfast leadership of Doctors Frederick L. Hall, Ph.D, and Erlinda M. Gordon, M.D., who continue serve as CEO and Chairman, respectively. Together, they raised over seven million dollars in academic research funding needed to fully-develop the core biotechnologies, followed by an additional 35 million dollars in investment capital with which they successfully guided the transition of Epeius Biotechnologies from an academic startup to a free standing, revenue-generating biopharmaceutical company. Leading the field of genetic medicine forward where many others have failed, these visionary business builders have developed an intellectual property portfolio that is the envy of the biopharmaceutical industry; they have validated the company’s lead product(s) in the crucible of clinical medicine, and have virtually established the emerging field of pathotropic (or disease-seeking) medicine.
Under the leadership of Drs. Hall and Gordon, Epeius Biotechnologies has (i) gained exclusive licensing rights for all of the targeting and molecular-genetic technologies embodied in Rexin-G, (ii) conducted international clinical trials which validated the lead product, (iii) advanced the yield of biopharmaceutical GMP through a series of major technological innovations, (iv) attained Orphan Drug Status through the US FDA, (v) gained product registration for Rexin-G for all solid tumors from Philippine BFAD, (vi) generated the company’s first million dollars in revenues through product sales, and (vii) initiated a corporate outreach program to facilitate the development of strategic alliances and corporate partnering. Thus, in addition to leading the advancement of bioscience and medicine from “the bench to the bedside” in a manner that is unprecedented in modern times, the senior management team of Epeius Biotechnologies continues to raise the bar for the biopharmaceutical industry in terms of corporate productivity, R&D efficiency, and significant drug development.
Academic Background: Dr. Hall, a Phi Beta Kappa scholar, received his bachelor’s degree in Biology from the University of Colorado at Boulder and his Ph.D. degree in Physiology and Biophysics from Colorado State University. He gained advanced training in Biochemistry and Molecular Biology as a NATO exchange scientist at the University of Dundee, Scotland, and as a postdoctoral scholar at the University of California at Davis. Dr. Hall is recognized worldwide for his pioneering work on the molecular and genetic mechanisms of cell growth and cell cycle control. His research laboratory was credited with the molecular cloning of several critical cell cycle control genes, including the cyclin G1 gene which represents a critical proto-oncogene that is over-expressed in numerous cancer cells.
Erlinda M. Gordon, M.D.
Founder, VP of Operations and Medical Affairs
Prior to founding the Company, Dr. Gordon held the following positions at the Keck School of Medicine of the University of Southern California, where she was employed for 15 years: Associate Professor of Pediatrics, Medical Director of the Vector Production Unit, and Director of the Molecular Therapeutics Division of the Gene Therapy Laboratories. Her long-standing contributions to cancer research began with her work on the novel cancer drug VM26, for treatment of acute monoblastic leukemia in infants (published in Blood, 1984). Dr. Gordon is recognized for her original research and extensive publication history in the field of gene therapy. She was recipient of a Research Career Development Award from the NIH, and has extensive experience in Phase I through IV NIH-sponsored clinical trials for pediatric cancer (Childrens Cancer Study Group) and hemophilia. Dr. Gordon is the FDA liaison and Gene Therapy Sponsor for Phase I/II clinical trials of Rexin-G® for metastatic sarcoma, breast cancer and pancreatic cancer and a Phase II pivotal study of Rexin-G® for metastatic osteosarcoma in the United States.
Under the leadership of Drs. Hall and Gordon, Epeius Biotechnologies has (i) gained exclusive licensing rights for all of the targeting and molecular-genetic technologies embodied in Rexin-G, (ii) conducted international clinical trials which validated the lead product, (iii) advanced the yield of biopharmaceutical GMP through a series of major technological innovations, (iv) attained Orphan Drug Status through the US FDA, (v) gained product registration for Rexin-G for all solid tumors from Philippine BFAD, (vi) generated the company’s first million dollars in revenues through product sales, and (vii) initiated a corporate outreach program to facilitate the development of strategic alliances and corporate partnering. Thus, in addition to leading the advancement of bioscience and me dicine from “the bench to the bedside” in a manner that is unprecedented in modern times, the senior management team of Epeius Biotechnologies continues to raise the bar for the biopharmaceutical industry in terms of corporate productivity, R&D efficiency, and significant drug development.
Dr. Gordon is a board certified pediatric hematologist-oncologist and received her M.D. degree (cum laude) in 1971 from the University of Santo Tomas School of Medicine and Surgery in Manila, Philippines, and her pediatric residency and hematology-oncology fellowship training at Case Western Reserve University School of Medicine in Cleveland, Ohio.